RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205

Cancer Research

Volumn 67, Issue 18, 2007, Pages 8856-8864

  Li, Jonathan Chi Hang ^a   Li, Ronghao ^a  

^a Raven Biotechnologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CARBOHYDRATE; CHIMERIC ANTIBODY; EPITOPE; IMMUNOGLOBULIN G1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE B; RAV12 ANTIBODY; SOMATOMEDIN C RECEPTOR; TYRPHOSTIN; TYRPHOSTIN AG 538; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN COLO201; CELL STRAIN COLO205; CELL STRAIN SNNU 16; CELL SURVIVAL; COLON TUMOR; CONTROLLED STUDY; DESENSITIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH TUMOR; XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HT29 CELLS; HUMANS; IMMUNOGLOBULIN G; INSULIN-LIKE GROWTH FACTOR I; MEMBRANE PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 34548792419     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0971     Document Type: Article

References (50)

1. Roskoski R, Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1-11.
2. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004;122:598-609.
3. Coppola D, Ferber A, Miura M, et al. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 1994;14:4588-95.
4. Adams TE, McKern NM, Ward CW. Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors 2004;22:89-95.
5. Roudabush FL, Pierce KL, Maudsley S, et al. Transactivation of the EGF receptor mediates IGF-I-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 2000;275:22583-9.
6. Mulligan C, Rochford J, Denyer G, et al. Microarray analysis of insulin and insulin-like growth factor-1 (IGF-I) receptor signaling reveals the selective upregulation of the mitogen heparin-binding EGF-like growth factor by IGF-I. J Biol Chem 2002;277:42480-7.
7. Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215-44.
8. Romano G. The complex biology of the receptor for the insulin-like growth factor-1. Drug News Perspect 2003;16:525-31.
9. Brodt P, Samani A, Navab R. Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy. Biochem Pharmacol 2000;60:1101-7.
10. Bahr C, Groner B. The insulin like growth factor-1 receptor (IGF-IR) as a drug target: novel approaches to cancer therapy. Growth Horm IGF Res 2004;14:287-95.
11. White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994;269:1-4.
12. De Meyts P, Wallach B, Christoffersen CT, et al. The insulin-like growth factor-I receptor. Structure, ligand-binding mechanism and signal transduction. Horm Res 1994;42:152-69.
13. White MF. Insulin Signaling Pathway. Sci STKE (connections map) http://stke.sciencemag.org/ 2005.
14. Lee CT, Park KH, Adachi Y, et al. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene Ther 2003;10:57-63.
15. Liu X, Turbyville T, Fritz A, et al. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res 1998;58:5432-8.
16. Steller MA, Delgado CH, Bartels CJ, et al. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 1996;56:1761-5.
17. Kucab JE, Dunn SE. Role of IGF-IR in mediating breast cancer invasion and metastasis. Breast Dis 2003;17:41-7.
18. Wu Y, Yakar S, Zhao L, et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002;62:1030-5.
19. Gil-Ad I, Shtaif B, Luria D, et al. Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture. Growth Horm IGF Res 1999;9:458-64.
20. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17:1595-606.
21. Decraene D, Agostinis P, Bouillon R, et al. Insulin-like growth factor-1-mediated AKT activation postpones the onset of ultraviolet B-induced apoptosis, providing more time for cyclobutane thymine dimer removal in primary human keratinocytes. J Biol Chem 2002;277:32587-95.
22. Remacle-Bonnet MM, Garrouste FL, Heller S, et al. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor a-induced mitogen-activated protein kinase and nuclear factor κB signaling pathways. Cancer Res 2000;60:2007-17.
23. Dunn SE, Hardman RA, Kari FW, et al. Insulin-like growth factor 1 (IGF-I) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997;57:2687-93.
24. Bahr C, Groner B. The IGF-I receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-IR function. Growth Factors 2005;23:1-14.
25. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11:2063-73.
26. Resnicoff M, Coppola D, Sell C, et al. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 1994;54:4848-50.
27. Adachi Y, Lee CT, Carbone DP. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy. Novartis Found Symp 2004;262:177-89.
28. Schneider JW, Chang AY, Rocco TP. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol 2001;28:18-26.
29. Gregorou M, Rees AR. Properties of a monoclonal antibody to epidermal growth factor receptor with implications for the mechanism of action of EGF. EMBO J 1984;3:929-37.
30. Gooi HC, Picard JK, Hounsell EF, et al. Monoclonal antibody (EGR/G49) reactive with the epidermal growth factor receptor of A431 cells recognizes the blood group ALeb and ALey structures. Mol Immunol 1985;22:689-93.
31. Klinger M, Farhan H, Just H, et al. Antibodies directed against Lewis-Y antigen inhibit signaling of Lewis-Y modified ErbB receptors. Cancer Res 2004;64:1087-93.
32. Loo D, Pryer N, Young P, et al. The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther 2007;6:856-65.
33. Blum G, Gazit A, Levitzki A. Substrate competitive inhibitors of IGF-I receptor kinase. Biochemistry 2000;39:15705-12.
34. Rosenzweig SA, Zetterstrom C, Benjamin A. Identification of retinal insulin receptors using site-specific antibodies to a carboxyl-terminal peptide of the human insulin receptor a-subunit. Up-regulation of neuronal insulin receptors in diabetes. J Biol Chem 1990;265:18030-4.
35. Yamasaki H, Prager D, Melmed S. Structure-function of the human insulin-like growth factor-I receptor: a discordance of somatotroph internalization and signaling. Mol Endocrinol 1993;7:681-5.
36. Prager D, Li HL, Yamasaki H, et al. Human insulin-like growth factor I receptor internalization. Role of the juxtamembrane domain. J Biol Chem 1994;269:11934-7.
37. Stannard B, Blakesley V, Kato H, et al. Single tyrosine substitution in the insulin-like growth factor I receptor inhibits ligand-induced receptor autophosphorylation and internalization, but not mitogenesis. Endocrinology 1995;136:4918-24.
38. Miura M, Baserga R. The tyrosine residue at 1250 of the insulin-like growth factor I receptor is required for ligand-mediated internalization. Biochem Biophys Res Commun 1997;239:182-5.
39. Romanelli A, Martin KA, Toker A, et al. p70 S6 kinase is regulated by protein kinase C~ and participates in a phosphoinositide 3-kinase-regulated signalling complex. Mol Cell Biol 1999;19:2921-8.
40. Song YH, Godard M, Li Y, et al. Insulin-like growth factor I-mediated skeletal muscle hypertrophy is characterized by increased mTOR-p70S6K signaling without increased Akt phosphorylation. J Investig Med 2005;53:135-42.
41. Mamay CL, Mingo-Sion AM, Wolf DM, et al. An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer. Oncogene 2003;22:602-14.
42. Rane MJ, Coxon PY, Powell DW, et al. p38 Kinase-dependent MAPKAPK-2 activation functions as 3-phosphoinositide-dependent kinase-2 for Akt in human neutrophils. J Biol Chem 2001;276:3517-23.
43. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004;23:77-99.
44. Dabelsteen E. Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol 1996;179:358-69.
45. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002;5:234-48.
46. Fresno Vara JA, Casado E, de Castro J, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204.
47. Kumar R, Hung MC. Signaling intricacies take center stage in cancer cells. Cancer Res 2005;65:2511-5.
48. Read LC, Lemmey AB, Howarth GS, et al. The gastrointestinal tract is one of the most responsive target tissues for IGF-I and its potent analogs. In: Spencer EM, editor. Modern concepts of insulin-like growth factors. New York: Elsevier Science; 1991. p. 225-34.
49. Meroni PL, Raschi E, Testoni C, et al. Endothelial cell activation by antiphospholipid antibodies. Clin Immunol 2004;112:169-74.
50. Rotzschke O, Falk K, Strominger JL. Superactivation of an immune response triggered by oligomerized T cell epitopes. Proc Natl Acad Sci U S A 1997;94:14642-7.